Duration of physical restraint use ‐ not measured · older people in all long‐term care settings
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Falls · older people in all long‐term care settings
1 finding from 1 review
Fall‐related injuries ‐ not measured · older people in all long‐term care settings
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Residents with at least one psychotropic medication ‐ not measured · older people in all long‐term care settings
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Residents with at least one belt · older people in all long‐term care settings
Summary of findings table ‐ Organisational intervention probably leads to lower residents with at least one belt compared with usual care (moderate certainty).
1 finding from 1 review
Serious adverse events related to the use of physical restraints · older people in all long‐term care settings
1 finding from 1 review
Duration of physical restraint use · older people in all long‐term care settings
1 finding from 1 review
Falls · older people in all long‐term care settings
Summary of findings table ‐ Organisational intervention showed no clear difference in residents with at least one fall compared with usual care (low certainty).
1 finding from 1 review
Number of people sustaining one or more fall‐related fractures · older people in all long‐term care settings
Summary of findings table ‐ Organisational intervention showed no clear difference in residents with at least one fall‐related fracture compared with usual care (low certainty).
1 finding from 1 review
Residents with at least one psychotropic medication · older people in all long‐term care settings
Summary of findings table ‐ Organisational intervention showed no clear difference in residents with at least one psychotropic medication compared with usual care (moderate certainty).
1 finding from 1 review
Residents with at least one physical restraint · older people in all long‐term care settings
1 finding from 1 review
Serious adverse events ‐ not measured · older people in all long‐term care settings
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cumulative incidence of herpes zoster, 3.1 years · healthy older adults aged ≥ 60 years
Live zoster vaccine probably leads to lower cumulative incidence of herpes zoster, 3.1 years compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ serious adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ serious adverse eventsClinical or… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects of any severity (systemic symptoms) · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any systemic symptomClinical… compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ potential immune‐mediated disease Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ potential immune‐mediated… compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ any local symptom Clinical criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any local symptomClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
Dropouts ‐ did not receive second dose Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher dropouts ‐ did not receive second doseClinical or laboratory criteria compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine probably leads to higher participants with adverse eventsClinical or laboratory criteria compared with placebo (moderate certainty).
1 finding from 1 review
DeathClinical criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in deathClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review